Amicus Therapeutics, Inc. Company Review & Valuation

FOLD
Nasdaq
Latest Price
10.16USD
Market Capitalization
2.72bUSD

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases.

The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease.

It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies.

Amicus Therapeutics, Inc.

was founded in 2002 and is headquartered in Cranbury, New Jersey.

Industry
Biotechnology
HQ Location
Cranbury, New Jersey

Stock Price

Price data not available for Amicus Therapeutics, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl